Recently, Lawrence Lesko, the director of the FDA Office of Clinical Pharmacology and Biopharmaceuticals, Center for Drug Evaluation and Research, noted that insurers are beginning to provide reimbursement for genetics testing and other elements of personalized medicine. His belief is that support for genetics-based medicine must come from insurance providers before personalized medicine becomes the norm.
Guest Speaker
- Aidan Toombs, Crescendo Bioscience
Topics to be discussed include:
- Opportunities and challenges of current and future technology applications
- Return on investment in personalized medicine technology
- Reimbursement issues and product coding, including ways to avoid potential minefields and traps
Foley Speakers
- Judy Waltz, Partner and Co-Chair, Life Sciences Industry Team
- Antoinette Konski, Session Moderator, Partner and member, Chemical, Biotechnology & Pharmaceutical Practice
Foley & Lardner LLP will apply for CLE credit after the program, wherever applicable. Foley & Lardner LLP certifies that this activity has been approved for California MCLE credits by the State Bar of California in the amount of one General credit. Foley & Lardner LLP is a State Bar of California MCLE approved provider.